NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Market Activity Driven by Corporate Developments and Earnings Updates

May 25 marked a day of significant market activity as several stocks remained in focus due to various corporate developments, earnings updates, and regulatory triggers. The day's trading activity was influenced by the performance of key companies, including NTPC and Eicher Motors, which reported notable changes in their quarterly earnings.

NTPC's shares traded flat despite the company reporting a 34.4% year-on-year increase in consolidated net profit for Q4 at Rs 10,615 crore, compared to Rs 7,897.1 crore in the same period last year. However, revenue from operations declined marginally by 0.3% YoY to Rs 49,687.8 crore from Rs 49,833.7 crore.

CompanyQ4 Net Profit (YoY)Revenue (YoY)
NTPC34.4%-0.3%
Hindalco Industries-50.9%20.4%
Eicher Motors11.6%16%

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

In contrast, Hindalco Industries shares declined more than 2 percent after the company posted a 50.9% YoY fall in consolidated net profit to Rs 2,597 crore for the fourth quarter, compared to Rs 5,284 crore a year earlier. Despite the sharp decline in profitability, revenue rose 20.4% YoY to Rs 78,133 crore from Rs 64,890 crore.

Eicher Motors shares gained 5 percent after the automaker reported an 11.6% increase in Q4 consolidated net profit at Rs 1,520 crore versus Rs 1,362.2 crore in the year-ago period. Revenue from operations surged 16% YoY to Rs 6,080.1 crore from Rs 5,241.1 crore.

Gujarat Themis Biosyn shares rose 6.5 percent after the company entered into a definitive agreement to acquire a 100% equity stake in MicroBiopharm Japan Co from funds managed or advised by Japan-based private equity firm T Capital Partners Co. The acquisition, valued at Rs 1,300 crore, is expected to be completed in Q2 FY2027.

Aurobindo Pharma shares fell 1 percent after the United States Food and Drug Administration (US FDA) classified the Telangana-based facility of subsidiary Eugia Pharma Specialities as Official Action Indicated (OAI) following an inspection conducted between February 16 and February 27. The inspection concluded with four observations.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

RBL Bank shares added nearly 2 percent after Emirates NBD Bank announced an open offer to acquire up to 41.55 crore shares from public shareholders, representing 26% of the expanded voting share capital of the bank, at Rs 282.38 per share. The total size of the open offer is estimated at Rs 11,735.3 crore.

Market participants said news flow remains a key driver in the current environment, with investors closely tracking corporate announcements and sector-specific triggers. With earnings season in progress, company-specific updates are expected to drive further volatility.

Investor Takeaway

Investors should focus on the earnings updates and corporate developments driving market activity.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.